Neumora Therapeutics Past Earnings Performance
Past criteria checks 0/6
Neumora Therapeutics's earnings have been declining at an average annual rate of -17.4%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually.
Key information
-17.4%
Earnings growth rate
39.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -59.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Neumora Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -254 | 50 | 159 |
| 31 Dec 23 | 0 | -236 | 45 | 143 |
| 30 Sep 23 | 0 | -155 | 41 | 127 |
| 30 Jun 23 | 0 | -132 | 34 | 108 |
| 31 Mar 23 | 0 | -123 | 33 | 99 |
| 31 Dec 22 | 0 | -131 | 31 | 92 |
| 30 Sep 22 | 0 | -130 | 32 | 87 |
| 30 Jun 22 | 0 | -278 | 30 | 79 |
| 31 Mar 22 | 0 | -265 | 29 | 66 |
| 31 Dec 21 | 0 | -237 | 25 | 56 |
| 30 Sep 21 | 0 | -230 | 21 | 47 |
| 31 Dec 20 | 0 | -99 | 8 | 17 |
Quality Earnings: NMRA is currently unprofitable.
Growing Profit Margin: NMRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NMRA is unprofitable, and losses have increased over the past 5 years at a rate of 17.4% per year.
Accelerating Growth: Unable to compare NMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NMRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).
Return on Equity
High ROE: NMRA has a negative Return on Equity (-59.83%), as it is currently unprofitable.